Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 1/2 6Phase 1 3Phase 3 2Phase NA 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Plasma cell 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Hematologic Neoplasms 1

Interventions

Specimen Handling 146pembrolizumab 118Magnetic Resonance Spectroscopy 117Cyclophosphamide 113Biopsy 96fludarabine 88Nivolumab 52Carboplatin 51Cisplatin 47Gemcitabine 46Radiotherapy 41venetoclax 40Cetuximab 40fludarabine phosphate 39Paclitaxel 39Ipilimumab 34atezolizumab 33Fluorouracil 33Bevacizumab 32Oxaliplatin 27Leucovorin 27Dexamethasone 26durvalumab 25X-Rays 25Irinotecan 25Radiation 24Cytarabine 23Azacitidine 23Injections 22Temozolomide 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Whole-Body Irradiation × 90 days × Clear all
NCT07162038 2026-06-05

Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
155 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT04579523 2026-06-04

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

Fred Hutchinson Cancer Center

Phase 1 Not yet recruiting
30 enrolled
Plasma cell

Multiple Myeloma

NCT02443831 2026-05-22

CARPALL: Immunotherapy With CD19+CD22 CAR T-cells for CD19+ and CD22+ Acute Lymphoblastic Leukaemia

University College, London

Phase 1 Recruiting
50 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡